Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Predict S.P.A. Class B ( (IT:PRE) ) has shared an update.
Predict S.p.A. has secured a 341-thousand-euro tender from the University of Rome Sapienza for a study on early colorectal cancer diagnosis using its Mistral breath sampler and machine learning algorithms. This project, in collaboration with the University of Bari and University of Salento, aims to validate breath analysis as a non-invasive, cost-effective diagnostic method, potentially revolutionizing early detection pathways and benefitting patients and the National Health System by offering a reliable alternative to conventional screening methods.
More about Predict S.P.A. Class B
Predict S.p.A. is an innovative SME based in Bari, operating in the healthcare sector. It specializes in in vivo diagnostics, focusing on ultrasound and radiological equipment distribution, and developing technologies in breath analysis and digital healthcare. The company is structured into four Strategic Business Units, providing solutions for diagnostic imaging, breath analysis innovations, and augmented reality and robotics technologies for healthcare professionals.
YTD Price Performance: -12.54%
Average Trading Volume: 9,321
For an in-depth examination of PRE stock, go to TipRanks’ Stock Analysis page.